\u75c5\u60c5\u56de\u6eaf<\/p>\n
9\u5c81\u5b66\u9f84\u671f\u7537\u7ae5\uff0c\u6025\u6027\u8d77\u75c5\uff0c\u75c5\u53f28\u5929\u3002\u8868\u73b0\u56db\u80a2\u80a2\u4f53\u65e0\u529b\uff0c\u53cc\u4e0b\u80a2\u5f00\u59cb\u9010\u6e10\u6ce2\u53ca\u53cc\u4e0a\u80a2\uff0c\u8fd1\u7aef\u91cd\u4e8e\u8fdc\u7aef\uff0c\u5e76\u8fdb\u884c\u6027\u52a0\u91cd\uff0c\u53d1\u75c5\u524d20\u5929\u6709\u547c\u5438\u9053\u611f\u67d3\u75c5\u53f2\u3002\u67e5\u4f53\uff0c\u53cc\u4e0a\u80a25-\u7ea7\uff0c\u53cc\u4e0b\u80a2\u8fd1\u7aef\u808c\u529b4-\u7ea7\uff0c\u53cc\u4e0b\u80a2\u8fdc\u7aef\u808c\u529b4\u7ea7\uff0c\u5de6\u4fa7\u80a2\u4f53\u529b\u91cf\u8f83\u53f3\u4fa7\u5f31\u3002\u53cc\u4e0b\u80a2\u808c\u5f20\u529b\u504f\u4f4e\uff0c\u53cc\u4fa7\u80b1\u4e8c\u5934\u808c\u8171\u53cd\u5c04\u7a0d\u5f31\uff0c\u53cc\u4fa7\u819d\u8171\u53cd\u5c04\u51cf\u5f31\uff0c\u53cc\u4fa7\u5df4\u6c0f\u5f81\u9634\u6027\uff0c\u8111\u810a\u6db2\u5e38\u89c4\u3001\u751f\u5316\u6b63\u5e38\uff0c\u795e\u7ecf\u8282\u82f7\u8102\u6297\u4f53\u8c31\u68c0\u6d4b\uff08\u8840\u6e05\uff09\uff1a\u6297GM4\u7b49\u6297\u4f53\u9633\u6027\uff08+\uff09\uff1b\u808c\u7535\u56fe\uff1a\u56db\u80a2\u5468\u56f4\u795e\u7ecf\u6027\u635f\u5bb3\uff0c\u611f\u89c9\u3001\u8fd0\u52a8\u7ea4\u7ef4\u5747\u53d7\u7d2f\u3002<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81(Guillain-Barr\u00e9 syndrome, GBS)\u662f\u4e00\u79cd\u514d\u75ab\u4ecb\u5bfc\u7684\u6025\u6027\u591a\u53d1\u6027\u795e\u7ecf\u75c5\uff0cGBS\u662f\u6025\u6027\u83b7\u5f97\u6027\u808c\u65e0\u529b\u6700\u5e38\u89c1\u7684\u75c5\u56e0\u4e4b\u4e00\uff0c\u5e38\u7531\u524d\u9a71\u611f\u67d3\u8bf1\u53d1\u3002\u90e8\u5206GBS\u60a3\u8005\u53ef\u80fd\u5e76\u53d1\u547c\u5438\u8870\u7aed\u548c\u81ea\u4e3b\u795e\u7ecf\u529f\u80fd\u969c\u788d\u3002\u8fd9\u79cd\u514d\u75ab\u53cd\u5e94\u53ef\u9488\u5bf9\u5468\u56f4\u795e\u7ecf\u7684\u9ad3\u9798\u6216\u8f74\u7d22\u3002<\/p>\n
GBS\u7684\u4e3b\u8981\u75c5\u53d8\u662f\u6025\u6027\u708e\u75c7\u6027\u8131\u9ad3\u9798\u6027\u591a\u795e\u7ecf\u6839\u795e\u7ecf\u75c5(acute inflammatory demyelinating polyradiculopathy, AIDP)\u548c\u6025\u6027\u8f74\u7d22\u53d8\u6027\uff0c\u540e\u8005\u5c24\u5176\u89c1\u4e8e\u5f2f\u66f2\u6746\u83cc(Campylobacter)\u76f8\u5173\u75be\u75c5\u60a3\u8005\u3002<\/p>\n
\u6d41\u884c\u75c5\u5b66<\/p>\n
GBS\u5728\u5168\u740318\u5c81\u53ca\u4ee5\u4e0b\u4eba\u7fa4\u4e2d\u7684\u5e74\u53d1\u75c5\u7387\u4e3a0.34-1.34\/100,000\u3002\u5c3d\u7ba1\u6240\u6709\u5e74\u9f84\u6bb5\u5747\u53ef\u53d7\u7d2f\uff0c\u4f46\u513f\u7ae5\u4e2d\u7684\u53d1\u75c5\u7387\u4f4e\u4e8e\u6210\u4eba\u300210\u5c81\u4ee5\u4e0a\u4eba\u7fa4\u4e2d\uff0c\u5e74\u9f84\u6bcf\u589e\u52a010\u5c81\u5219\u53d1\u75c5\u7387\u5927\u7ea6\u589e\u52a020%\u30022\u5c81\u4ee5\u4e0b\u513f\u7ae5\u5f88\u5c11\u53d1\u751fGBS\u3002\u6240\u6709\u5e74\u9f84\u6bb5\u4e2d\u7537\u5973\u53d1\u75c5\u6bd4\u4f8b\u7ea6\u4e3a1.5:1\u3002<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u4e34\u5e8a\u8868\u73b0<\/p>\n
\u4e00\u9879\u7eb3\u516595\u4f8bGBS\u513f\u7ae5\u7684\u524d\u77bb\u6027\u75c5\u4f8b\u7cfb\u5217\u7814\u7a76\u4e2d\uff0c\u6700\u5e38\u89c1\u7684\u521d\u59cb\u75c7\u72b6\u4e3a\u6b65\u6001\u4e0d\u7a33\u3001\u795e\u7ecf\u75c5\u7406\u6027\u75bc\u75db\u548c\u4e0d\u80fd\u884c\u8d70\uff0c\u5206\u522b\u89c1\u4e8e45%\u300134%\u548c24%\u7684\u75c5\u4f8b\u3002\u5230\u75c5\u7a0b\u9ad8\u5cf0\u65f6\uff0c\u75c7\u72b6\u7684\u53d1\u751f\u7387\u5982\u4e0b\uff1a<\/p>\n
\u25cf79%\u7684\u60a3\u8005\u6709\u795e\u7ecf\u75c5\u7406\u6027\u75bc\u75db\u3002<\/p>\n
\u25cf60%\u7684\u60a3\u8005\u65e0\u6cd5\u884c\u8d70\u3002<\/p>\n
\u25cf51%\u7684\u60a3\u8005\u6709\u81ea\u4e3b\u795e\u7ecf\u529f\u80fd\u969c\u788d\u3002\uff08\u591a\u79cd\u5fc3\u5f8b\u5931\u5e38(\u5fc3\u640f\u505c\u6b62\u3001\u5fc3\u52a8\u8fc7\u7f13\u3001\u6301\u7eed\u6027\u7aa6\u6027\u5fc3\u52a8\u8fc7\u901f\uff0c\u4ee5\u53ca\u623f\u6027\u548c\u5ba4\u6027\u5feb\u901f\u6027\u5fc3\u5f8b\u5931\u5e38)\u25cf\u76f4\u7acb\u6027\u4f4e\u8840\u538b\u25cf\u77ed\u6682\u6027\u6216\u6301\u7eed\u6027\u9ad8\u8840\u538b\u25cf\u9ebb\u75f9\u6027\u80a0\u6897\u963b\u25cf\u8180\u80f1\u529f\u80fd\u969c\u788d\u25cf\u51fa\u6c57\u5f02\u5e38\uff09<\/p>\n
\u25cf46%\u7684\u60a3\u8005\u5b58\u5728\u9885\u795e\u7ecf\u53d7\u7d2f\u3002\uff08\u9885\u795e\u7ecf\u75c5\u53d8\u6700\u5e38\u7d2f\u53ca\u9762\u795e\u7ecf\uff0c\u5bfc\u81f4\u53cc\u4fa7\u9762\u808c\u65e0\u529b\u3002\uff09<\/p>\n
\u25cf24%\u7684\u60a3\u8005\u4e0d\u80fd\u4f7f\u7528\u53cc\u81c2\u3002<\/p>\n
\u25cf13%\u7684\u60a3\u8005\u9700\u8981\u673a\u68b0\u901a\u6c14\u3002<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u7684\u4e9a\u578b<\/p>\n
GBS\u7684\u6bcf\u79cd\u7c7b\u578b\u5747\u6709\u7279\u5f81\u6027\u7684\u4e34\u5e8a\u3001\u75c5\u7406\u751f\u7406\u5b66\u548c\u75c5\u7406\u5b66\u8868\u73b0\u3002\u4e0a\u884c\u6027\u9ebb\u75f9\u8fd9\u4e00\u7ecf\u5178\u8868\u73b0\u6700\u4e3a\u5e38\u89c1\uff0c\u5982\u6025\u6027\u708e\u6027\u8131\u9ad3\u9798\u6027\u591a\u53d1\u795e\u7ecf\u6839\u795e\u7ecf\u75c5\uff08AIDP\uff09\uff0c\u6025\u6027\u8fd0\u52a8\u8f74\u7d22\u6027\u795e\u7ecf\u75c5\uff08acute motor axonal neuropathy\uff0cAMAN\uff09\uff0c\u4f46\u4e00\u4e9b\u975e\u5178\u578b\u4e9a\u578b\u8868\u73b0\u4e3a\u7279\u5b9a\u808c\u7fa4\u6216\u795e\u7ecf\u7684\u5c40\u90e8\u6216\u533a\u57df\u6027\u53d7\u7d2f\u3002\u4e00\u4e9b\u4e9a\u578b\u6709\u663e\u8457\u9885\u795e\u7ecf\u53d7\u7d2f\uff0c\u5305\u62ecMiller-Fisher\u7efc\u5408\u5f81(Miller Fisher syndrome, MFS)\u3001Bickerstaff\u8111\u5e72\u8111\u708e\u3001\u591a\u9885\u795e\u7ecf\u708e\u53ca\u54bd-\u9888-\u81c2\u65e0\u529b\u3002\u5176\u4ed6\u5305\u62ec\u7eaf\u611f\u89c9\u6027\u795e\u7ecf\u75c5\u53ca\u6025\u6027\u6cdb\u81ea\u4e3b\u795e\u7ecf\u529f\u80fd\u969c\u788d\u3002<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u8bca\u65ad<\/p>\n
GBS\u7684\u8bca\u65ad\u57fa\u4e8e\u60a3\u8005\u75c5\u53f2\u548c\u795e\u7ecf\u5b66\u3001\u7535\u751f\u7406\u548c\u8111\u810a\u6db2\u68c0\u67e5\u3002<\/p>\n
GBS\u7684\u5178\u578b\u4e34\u5e8a\u7279\u5f81\u662f\u4e3b\u8981\u4e3a\u5bf9\u79f0\u6027\u6216\u7a0d\u5fae\u4e0d\u5bf9\u79f0\u6027\u7684\u8fdb\u884c\u6027\u808c\u65e0\u529b\uff0c\u4ee5\u53ca\u6df1\u8171\u53cd\u5c04\u6d88\u5931\u6216\u51cf\u5f31\u3002\u808c\u65e0\u529b\u7a0b\u5ea6\u5404\u5f02\uff0c\u8f7b\u5219\u8f7b\u5ea6\u884c\u8d70\u56f0\u96be\uff0c\u91cd\u5219\u6240\u6709\u80a2\u4f53\u808c\u3001\u9762\u808c\u3001\u547c\u5438\u808c\u548c\u5ef6\u9ad3\u808c\u8fd1\u4e4e\u5b8c\u5168\u9ebb\u75f9\u3002<\/p>\n
\u5173\u4e8eAIDP\u7684\u8bca\u65ad\uff1a<\/p>\n
\uff081\uff09\u5e38\u6709\u524d\u9a71\u611f\u67d3\u53f2\uff0c\u5448\u6025\u6027\u8d77\u75c5\uff0c\u8fdb\u884c\u6027\u52a0\u91cd\uff0c\u591a\u57284\u5468\u5185\u8fbe\u9ad8\u5cf0\u3002<\/p>\n
\uff082\uff09\u5bf9\u79f0\u6027\u80a2\u4f53\u548c\u5ef6\u9ad3\u652f\u914d\u808c\u8089\u3001\u9762\u90e8\u808c\u8089\u65e0\u529b\uff0c\u91cd\u8005\u6709\u547c\u5438\u808c\u65e0\u529b\u3002\u56db\u80a2\u8171\u53cd\u5c04\u51cf\u4f4e\u6216\u6d88\u5931\u3002<\/p>\n
\uff083\uff09\u53ef\u4f34\u6709\u611f\u89c9\u5f02\u5e38\u548c\u81ea\u4e3b\u795e\u7ecf\u529f\u80fd\u969c\u788d\u3002<\/p>\n
\uff084\uff09\u8111\u810a\u6db2\u51fa\u73b0\u86cb\u767d-\u7ec6\u80de\u5206\u79bb\u73b0\u8c61\u3002<\/p>\n
\uff085\uff09\u7535\u751f\u7406\u68c0\u67e5\u63d0\u793a\u8fd0\u52a8\u795e\u7ecf\u4f20\u5bfc\u8fdc\u7aef\u6f5c\u4f0f\u671f\u5ef6\u957f\u3001\u4f20\u5bfc\u901f\u5ea6\u51cf\u6162\u3001F\u6ce2\u5f02\u5e38\u3001\u4f20\u5bfc\u963b\u6ede\u3001\u5f02\u5e38\u6ce2\u5f62\u79bb\u6563\u7b49\u5468\u56f4\u795e\u7ecf\u8131\u9ad3\u9798\u6539\u53d8\u3002<\/p>\n
\uff086\uff09\u75c5\u7a0b\u6709\u81ea\u9650\u6027\u3002<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u6cbb\u7597<\/p>\n
\u2460\u4e00\u822c\u6cbb\u7597\uff1a\u5fc3\u7535\u76d1\u62a4\u3001\u547c\u5438\u8425\u517b\u652f\u6301\u7b49\u3002<\/p>\n
\u2461\u514d\u75ab\u6cbb\u7597\uff1aGBS\u6cbb\u7597\u4e2d\u53ef\u9009\u62e9\u7684\u514d\u75ab\u6cbb\u7597\u836f\u7269\u5305\u62ecIVIG\u548c\u8840\u6d46\u4ea4\u6362\uff081\uff09IVIG\u6cbb\u7597\u65b9\u6848\uff1a400 mg\u00b7kg\u00b7d-1\uff0c1\u6b21\/d\uff0c\u9759\u8109\u6ef4\u6ce8\uff0c\u8fde\u7eed3~5 d\u3002\uff082\uff09\u8840\u6d46\u4ea4\u6362\u6cbb\u7597\u65b9\u6848\uff1a\u6bcf\u6b21\u8840\u6d46\u4ea4\u6362\u91cf\u4e3a\u6bcf\u5343\u514b\u4f53\u91cd30~50 ml\uff0c\u57281~2\u5468\u5185\u8fdb\u884c3-5\u6b21\u3002<\/p>\n
\u2462\u6fc0\u7d20\uff1a\u5173\u4e8e\u7cd6\u76ae\u8d28\u6fc0\u7d20\u5728GBS \u6cbb\u7597\u4e2d\u7684\u4ef7\u503c\u56fd\u5916\u591a\u9879\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5747\u663e\u793a\u5355\u72ec\u5e94\u7528\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597GBS\u65e0\u660e\u786e\u7597\u6548\uff0c\u7cd6\u76ae\u8d28\u6fc0\u7d20\u548cIVIG\u8054\u5408\u6cbb\u7597\u4e0e\u5355\u72ec\u5e94\u7528IVIG\u6cbb\u7597\u7684\u6548\u679c\u4e5f\u65e0\u663e\u8457\u5dee\u5f02\u3002\u56e0\u6b64\uff0c\u56fd\u5916\u7684GBS\u6307\u5357\u5747\u4e0d\u63a8\u8350\u5e94\u7528\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597 GBS\u3002<\/p>\n
\u2463\u795e\u7ecf\u8425\u517b\uff1a\u53ef\u5e94\u7528B\u65cf\u7ef4\u751f\u7d20\u6cbb\u7597\uff0c\u5305\u62ec\u7ef4\u751f\u7d20B1\u3001\u7ef4\u751f\u7d20B12\uff08\u7532\u94b4\u80fa\u3001\u6c30\u94b4\u80fa\uff09\u3001\u7ef4\u751f\u7d20B6\u7b49\u3002<\/p>\n
\u2464\u5eb7\u590d\u8bad\u7ec3\u3002<\/p>\n
\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u9884\u540e<\/p>\n
\u5927\u90e8\u5206GBS\u60a3\u8005\u75c5\u60c5\u57282\u5468\u5185\u8fbe\u5230\u9ad8\u5cf0\uff0c\u7ee7\u800c\u6301\u7eed\u6570\u5929\u81f3\u6570\u5468\u540e\u5f00\u59cb\u6062\u590d\uff0c\u5c11\u6570\u60a3\u8005\u5728\u75c5\u60c5\u6062\u590d\u8fc7\u7a0b\u4e2d\u51fa\u73b0\u6ce2\u52a8\u3002\u591a\u6570\u60a3\u8005\u795e\u7ecf\u529f\u80fd\u5728\u6570\u5468\u81f3\u6570\u6708\u5185\u57fa\u672c\u6062\u590d\uff0c\u5c11\u6570\u9057\u7559\u6301\u4e45\u7684\u795e\u7ecf\u529f\u80fd\u969c\u788d\u3002<\/p>\n
\u76ee\u524d\u5173\u4e8e\u513f\u7ae5\u9884\u540e\u7684\u6570\u636e\u8f83\u5c11\uff0c\u4e00\u4e9b\u6570\u636e\u63d0\u793a\u6b7b\u4ea1\u7387\u4e3a3%-4%\uff0c\u5e76\u4e14\u226590%\u7684\u60a3\u513f\u8fdc\u671f\u6062\u590d\u60c5\u51b5\u597d\u3002<\/p>\n
\u53c2\u8003\u6587\u732e<\/p>\n
1.Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barr\u00e9 syndrome: a prospective multicentre study. Neuropediatrics. 2007 Feb;38(1):10-7. <\/p>\n
2.Leonhard SE et.al Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019 Nov;15(11):671-683. doi: 10.1038\/s41582-019-0250-9. Epub 2019 Sep 20. PMID: 31541214; PMCID: PMC6821638.<\/p>\n
3.\u4e2d\u534e\u533b\u5b66\u4f1a\u795e\u7ecf\u75c5\u5b66\u5206\u4f1a\u7b49. \u4e2d\u56fd\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u8bca\u6cbb\u6307\u53572019. \u4e2d\u534e\u795e\u7ecf\u79d1\u6742\u5fd7\uff0c2019\uff0c52(11):877-882.<\/p>\n","protected":false},"excerpt":{"rendered":"
\u75c5\u60c5\u56de\u6eaf 9\u5c81\u5b66\u9f84\u671f\u7537\u7ae5\uff0c\u6025\u6027\u8d77\u75c5\uff0c\u75c5\u53f28\u5929\u3002\u8868\u73b0\u56db\u80a2\u80a2\u4f53\u65e0\u529b\uff0c\u53cc\u4e0b\u80a2\u5f00\u59cb\u9010\u6e10\u6ce2 … \u7ee7\u7eed\u9605\u8bfb